Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. PODCAST with dr. Lisa Salvatore about the primary analysis results of the phase II AVANA study, which
    evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced
    rectal cancer

2. Pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for unresectable or metastatic
    HER2-positive gastric or GEJ adenocarcinoma

3. Clinically meaningful survival advantage with 177Lu-DOTATATE in advanced midgut neuroendocrine
    tumours

4. No benefit from adding napabucasin to FOLFIRI in patients with previously treated metastatic colorectal
    cancer

5. Impact of FGFR2-rearrangements in treatment response to systemic therapies in cholangiocarcinoma